InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.90
(
0.13%
)
Bitcoin
65,053.20
(
-0.13%
)
Post# of 252254
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: stockbettor post# 123550

Wednesday, 07/20/2011 7:33:38 AM

Wednesday, July 20, 2011 7:33:38 AM

Post# of 252254

Obviously, Neugranin [from CoGenesys], which is albumin based, will be non-infringing.

I don't think so. CoGenesys's albumin fusion technology makes Neugranin a long-acting form of G-CSF (by increasing its bio-availability and half life), but it would still infringe Amgen's 5,580,755 and 5,582,823 patents (running until Dec. 2013), because the first covers all sequences coding for amino acid residues of hpG-CSF (the native as well as its analogs) and the other covers methods for treating patients with these protein sequences. I believe that is why Teva settled.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up